IBRX — Immunitybio Balance Sheet
0.000.00%
- $6.16bn
- $6.72bn
- $14.75m
- 22
- 15
- 92
- 38
Annual balance sheet for Immunitybio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-Q | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 96.1 | 317 | 107 | 266 | 150 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.99 | 1.33 | 1.89 | 3.17 | 2.65 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 112 | 334 | 141 | 294 | 185 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 90.7 | 119 | 190 | 183 | 170 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 221 | 469 | 362 | 504 | 383 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 68.1 | 369 | 501 | 58.3 | 54.9 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 341 | 711 | 810 | 1,091 | 872 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -120 | -242 | -447 | -587 | -489 |
| Total Liabilities & Shareholders' Equity | 221 | 469 | 362 | 504 | 383 |
| Total Common Shares Outstanding |